Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?

Benzinga_recent_news10-31

MediciNova Inc. (NASDAQ:MNOV) shares surged 87.39% to $2.23 in after-hours trading on Thursday. Check out the current price of MNOV stock here. The California-based biopharmaceutical company said on ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579480451?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/30/A-Businessman-In-A-Suit-Interacts-With-A.jpeg?optimize=medium&dpr=2&auto=webp&width=120","is_english":true,"pubTime":"2025-10-31 11:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579480451","market":"us","top_or_hot":-1,"title":"Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?","media":"Benzinga_recent_news","content":"<div>\n<p>MediciNova Inc. (NASDAQ:MNOV) shares surged 87.39% to $2.23 in after-hours trading on Thursday.\nCheck out the current price of MNOV stock here. \nThe California-based biopharmaceutical company said on ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/25/10/48549729/why-did-medicinova-stock-mnov-jump-over-87-in-after-hours-trading\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Did MediciNova Stock (MNOV) Jump Over 87% In After-Hours Trading?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-31 11:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/equities/25/10/48549729/why-did-medicinova-stock-mnov-jump-over-87-in-after-hours-trading><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MediciNova Inc. (NASDAQ:MNOV) shares surged 87.39% to $2.23 in after-hours trading on Thursday.\nCheck out the current price of MNOV stock here. \nThe California-based biopharmaceutical company said on ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/25/10/48549729/why-did-medicinova-stock-mnov-jump-over-87-in-after-hours-trading\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MNOV","symbol_name":"美第奇新星生物技术","start_time":0,"source_url":"https://www.benzinga.com/markets/equities/25/10/48549729/why-did-medicinova-stock-mnov-jump-over-87-in-after-hours-trading","article_id":"2579480451","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/30/A-Businessman-In-A-Suit-Interacts-With-A.jpeg?optimize=medium&dpr=2&auto=webp&width=120"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/10/48549729/why-did-medicinova-stock-mnov-jump-over-87-in-after-hours-trading","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2579480451","pubTimestamp":1761883020,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"MediciNova shares soared over 87% in after-hours trading on Thursday following the publication of promising research.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MNOV":"美第奇新星生物技术","BK4139":"生物科技"},"translate_title":"为什么MediciNova股票(MNOV)在盘后交易中上涨超过87%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNOV":1.5},"content_text":"MediciNova Inc. (NASDAQ:MNOV) shares surged 87.39% to $2.23 in after-hours trading on Thursday.\nCheck out the current price of MNOV stock here. \nThe California-based biopharmaceutical company said on Thursday that its research was published in the Journal of Atherosclerosis and Thrombosis, the official publication of the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Disease.\nThe study, \"Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis,\" was carried out in collaboration with a Japanese academic research group.\nAccording to the company, the study showed that MN-002, the primary metabolite of the oral bioavailable small molecule MN-001 (tipelukast), increased cholesterol efflux in macrophages by upregulating transport proteins ABCA1 and ABCG1.\nSee Also: Amazon Q3 FY2025 Earnings Call Transcript\nYuichi Iwaki, MediciNova president and CEO, said the collaborative research \"provides mechanistic insight into how MN-001 and its metabolite MN-002 may influence cholesterol and lipid metabolism.\"\nPrior clinical research demonstrated that MN-001 significantly impacted patients with Type 2 diabetes and improved serum lipid profiles in patients with hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD).\nThe clinical-stage company is nearing completion of enrollment for a randomized, placebo-controlled, double-blind Phase 2 study in patients with hypertriglyceridemia, type 2 diabetes, and NAFLD.\nMediciNova reported second-quarter earnings on Aug. 14, with a loss of 7 cents per share, beating the 10-cent loss analysts expected. Revenue totaled $134,600, exceeding expectations. \nThe company is scheduled to report third-quarter results Nov. 12.\nMediciNova's 52-week range is $1.13 to $2.55, and its market capitalization stands at $57.87 million.\nThe stock is down 44.13% year to date.\nPrice Action: According to Benzinga Pro data, MediciNova closed Thursday's regular session at $1.19, up 0.85%.\nBenzinga Edge Stock Rankings indicate that MNOV has a negative price trend across all time frames. Track the performance of other players in this segment.\nRead Next:\nPhoto Courtesy: meeboonstudio on Shutterstock.com\nDisclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579480451","isCrawlerRequest":true}